查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844196

獸用疫苗市場按產品類型、動物類型、疾病類型、給藥途徑和分銷管道分類 - 全球預測，2025-2032

Animal Vaccines Market by Product, Animal Type, Disease Type, Route of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用疫苗市場將成長至 234 億美元，複合年成長率為 6.93%。

主要市場統計數據
基準年2024年 136.9億美元
預計2025年 145.8億美元
預測年份：2032年 234億美元
複合年成長率（%） 6.93%

清晰且策略性地建立科學進步、相關人員壓力和商業需求，重新定義動物疫苗開發和部署的優先事項

獸用疫苗產業正處於關鍵時刻，科學創新、不斷變化的疾病動態以及相關人員不斷變化的期望正在重新定義製造商、獸醫和政策制定者的優先事項。分子生物學和免疫學的最新趨勢正在加速下一代疫苗的開發，伴侶動物和牲畜疾病預防需求的不斷成長也推動了對強大疫苗組合的需求。相關人員面臨著複雜的監管壓力、圍繞動物福利的倫理考慮以及成本效益和分銷靈活性的商業性需求。不斷變化的貿易政策、供應鏈的脆弱性以及對抗菌藥物管理的嚴格審查加劇了這些壓力，所有這些都將疫苗主導的預防策略置於永續動物健康計畫的核心。

在此背景下，各組織必須將科學機會與切實可行的交付模式結合，確保疫苗能送達最需要的動物。策略行動者必須優先進行能夠縮短從發現到現場部署時間的轉化研究，投資低溫運輸和替代給藥途徑以改善疫苗可及性，並積極與監管機構合作，降低研發過程中的風險。簡而言之，引言強調了將技術進步轉化為可擴展且具有韌性的疫苗接種解決方案的必要性，這些解決方案必須與獸醫學和畜牧業的實際情況相符。

平台創新、數位監管和不斷變化的監管預期將如何推動獸醫疫苗接種策略進入精準化、可及性和彈性的新時代

在科學突破、數位化實踐和不斷變化的流行病學壓力的推動下，獸用疫苗領域正在經歷重大變革。 mRNA 和重組方法等平台技術正在從實驗階段轉向標靶應用，實現更快的抗原設計和更精準的免疫調節。同時，去活化疫苗和減毒活病毒疫苗等傳統疫苗製劑在應對長期存在的分銷挑戰的同時，也不斷最佳化安全性和耐熱性。從基因組監測到供應鏈分析和遠端醫療等數位化工具，正在幫助更早發現疫情並加快疫苗宣傳活動，從而改變製造商規劃生產週期和分銷的方式。

在臨床方面，通用感染疾病風險的認知與畜牧業集約化生產之間的相互作用，推動了對保護範圍更廣、效力更持久的疫苗的需求。監管機構正在逐步調整其框架，以適應新技術，同時保持嚴格的安全標準，並鼓勵研發人員主動簡化核准流程。同時，獸醫和生產商等最終用戶要求疫苗能帶來明確的效益，包括改善畜群和伴侶動物的健康結果、易於管理以及符合抗菌藥物管理目標。這些因素共同重塑了投資重點，迫使現有企業和新參與企業調整其研發策略，包括可擴展的生產、改進的低溫運輸解決方案以及增強疫苗有效性的整合數據驅動服務。

2025 年關稅變化的連鎖營運和戰略影響正在重建整個獸用疫苗價值鏈的採購、製造本地化和分銷彈性。

美國2025年生效的關稅調整正在對整個動物疫苗價值鏈產生層層影響，影響籌資策略、生產經濟效益和全球貿易流動。部分投入品和生技藥品關稅的提高，促使製造商重新評估其供應商佈局，並加速關鍵生產過程的近岸外包和在地化。這些轉變並非單純受成本主導，而是反映了對疫苗生產中敏感生物成分（包括佐劑、管瓶和專用試劑）供應連續性的策略性重視。因此，各公司正在優先考慮雙重採購安排，並增加製造外包以減少對單點的依賴。

貿易政策的改變也影響分銷規劃。不斷上升的跨境成本促使經銷商和獸醫診所最佳化庫存策略，改善配方以延長產品保存期限，並探索替代管道以降低運輸複雜性。對出口商而言，關稅波動迫使其製定更複雜的定價和合約框架，以在關鍵地區保持競爭力；而進口商則必須協商達成長期供應協議，以減輕關稅突然波動帶來的影響。重要的是，關稅壓力增加了國內產能建設的興趣，促使公私部門就本地疫苗生產和勞動力發展獎勵展開討論。總而言之，這些因應措施正在創造一個更具韌性但又具有區域差異化的動物疫苗生產和分銷格局。

一個全面的細分框架，將產品形態、動物類別、目標疾病、給藥途徑和分銷管道結合起來，將支持差異化的開發和商業化方法

細分揭示了疫苗的開發、應用和商業化動態，需要根據產品類型、目標動物、疾病類別、給藥途徑和通路製定量身定做的策略。依產品類型，減毒活病毒疫苗、mRNA疫苗、重組疫苗和次單位疫苗，每種疫苗的研發時間、生產複雜性和低溫運輸依賴性各不相同。依動物類型，疫苗分為伴侶動物疫苗和牲畜疫苗，伴侶動物進一步分為貓和狗，牲畜進一步分為牛、雞、羊和豬。這種細分凸顯了家養寵物和牲畜在臨床需求、給藥方案和分銷模式方面的顯著差異，從而推動了不同的商業管道和傳播策略。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速部署mRNA和DNA疫苗平台以應對新出現的通用感染疾病威脅
  • 擴大自體疫苗的使用，以對抗豬群中農場特異性病原體的發生
  • 在禽流感控制中，擴大使用 DIVA 疫苗策略來區分感染動物和接種疫苗的動物
  • 全球市場上奈米顆粒佐劑增強馬流感疫苗免疫抗原性的進展
  • 針對反芻動物健康中多種梭菌和細菌病原體的聯合疫苗的出現
  • 擴大法規結構，支持在疾病爆發時有條件核准緊急動物疫苗
  • 利用農場數據分析和物聯網監控設備實施精準牲畜疫苗接種計劃
  • 對單劑量緩釋性的需求激增，以最佳化家禽免疫接種力度和依從性
  • 生物技術公司與獸醫服務提供者建立策略夥伴關係，在偏遠地區分發疫苗
  • 開發耐熱疫苗配方，以減少熱帶牲畜市場對低溫運輸的依賴

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：動物疫苗市場（按產品）

  • 去活化疫苗
  • 減毒活疫苗
  • mRNA疫苗
  • 重組疫苗
  • 次單位疫苗

9. 動物疫苗市場（依動物類型）

  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第 10 章：動物疫苗市場（依疾病類型）

  • 細菌感染疾病
    • 梭菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴氏桿菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第 11 章：按管理途徑分類的動物疫苗市場

  • 注射疫苗
    • 肌肉注射（IM）
    • 靜脈注射（IV）
    • 皮下（SC）
  • 口服疫苗

第 12 章：動物疫苗市場（依通路）

  • 網路藥局
  • 零售藥局
  • 獸醫診所

第 13 章：獸用疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章：動物疫苗市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的獸用疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Biogenesis Bago SA
    • BioVaxys Technology Corporation
    • Boehringer Ingelheim International GmbH
    • Brilliant Bio Pharma Private limited
    • Ceva Sante Animale
    • China Animal Husbandry Industry Co., Ltd.
    • Dalan Animal Health
    • Elanco Animal Health Inc.
    • Endovac Animal Health, LLC by Immvac Inc.
    • Hester Biosciences Limited
    • HIPRA, SA
    • Indian Immunologicals Limited
    • Kemin Industries, Inc.
    • Merck KGaA
    • Neogen Corporation
    • Phibro Animal Health Corporation
    • SAN Vet Holding GmbH
    • Sanofi SA
    • Seppic SA
    • Torigen Pharmaceuticals Inc.
    • Vaxxinova GmbH
    • VEROVACCiNES GmbH
    • Vetigenics, LLC
    • Vetoquinol SA
    • Virbac, Inc.
    • Zoetis Inc.
Product Code: MRR-ED54C46E8F03

The Animal Vaccines Market is projected to grow by USD 23.40 billion at a CAGR of 6.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.69 billion
Estimated Year [2025] USD 14.58 billion
Forecast Year [2032] USD 23.40 billion
CAGR (%) 6.93%

A clear, strategic framing of scientific progress, stakeholder pressures, and operational imperatives that redefine priorities for animal vaccine development and deployment

The animal vaccines sector sits at a pivotal junction where scientific innovation, shifting disease dynamics, and evolving stakeholder expectations converge to reshape priorities for manufacturers, veterinarians, and policymakers. Recent advances in molecular biology and immunology have accelerated the development of next-generation modalities, while rising demand for disease prevention across companion animals and livestock has intensified the need for robust vaccine portfolios. Stakeholders face a complex mix of regulatory rigor, ethical considerations around animal welfare, and the commercial imperatives of cost-efficiency and distribution agility. These pressures are compounded by changing trade policies, supply chain vulnerabilities, and heightened scrutiny on antimicrobial stewardship, all of which place vaccine-driven prevention strategies at the center of sustainable animal health programs.

Against this backdrop, organizations must synthesize scientific opportunities with pragmatic delivery models to ensure vaccines reach the animals that need them most. Strategic actors will prioritize translational research that shortens the time from discovery to field deployment, invest in cold-chain and alternative administration routes to improve access, and engage proactively with regulators to de-risk development pathways. In short, the introduction underscores a clear imperative: to transform technical progress into scalable, resilient immunization solutions that align with the operational realities of veterinary care and livestock production.

How platform innovations, digital surveillance, and evolving regulatory expectations are catalyzing a new era of precision, access, and resilience in animal immunization strategies

The landscape of animal vaccines is undergoing transformative shifts driven by scientific breakthroughs, digital-enabled practices, and changing epidemiological pressures. Platform technologies such as mRNA and recombinant approaches are moving from experimental phases into targeted applications, enabling faster antigen design and more precise immune modulation. At the same time, traditional modalities like inactivated and live attenuated vaccines continue to be optimized for safety profiles and thermostability, addressing long-standing distribution challenges. Digital tools-from genomic surveillance to supply chain analytics and telemedicine-are enabling earlier detection of outbreaks and more responsive vaccination campaigns, which in turn alter how manufacturers plan production cycles and distribution.

Clinically, the interplay between zoonotic risk awareness and the intensification of livestock production has intensified demand for vaccines that confer broader protection and longer durability. Regulatory bodies are gradually adapting frameworks to accommodate novel technologies while maintaining rigorous safety standards, prompting proactive engagement by developers to streamline approval paths. Meanwhile, end-users such as veterinarians and producers are demanding vaccines that offer clear returns in terms of herd or companion animal health outcomes, ease of administration, and compatibility with antimicrobial stewardship goals. Together, these forces are reshaping investment priorities, compelling incumbents and new entrants alike to align R&D strategies with scalable manufacturing, improved cold-chain solutions, and integrated data-driven services that amplify vaccine impact.

The cascading operational and strategic consequences of 2025 tariff changes that are reshaping sourcing, manufacturing localization, and distribution resilience across the animal vaccine value chain

United States tariff adjustments enacted in 2025 have created layered effects across the animal vaccine value chain, influencing sourcing strategies, production economics, and global trade flows. Increased duties on select inputs and finished biologics have incentivized manufacturers to reassess supplier footprints and to accelerate near-shoring or regionalization of critical production steps. These shifts are not merely cost-driven; they also reflect a strategic emphasis on controlling supply continuity for sensitive biologic components that underpin vaccine manufacturing, such as adjuvants, vials, and specialized reagents. As a result, organizations are prioritizing dual-sourcing arrangements and qualifying additional contract manufacturing partners to reduce single-point dependencies.

Trade policy changes have also affected distribution planning. Higher cross-border costs have encouraged distributors and veterinary services to optimize inventory strategies, extend product shelf-life through formulation improvements, and explore alternative channels that reduce transit complexity. For exporters, tariff volatility has required more sophisticated pricing and contractual frameworks to maintain competitiveness in key regions, while importers have negotiated long-term supply agreements to mitigate exposure to abrupt tariff swings. Importantly, tariff-induced pressures have heightened interest in domestic capacity building, prompting public-private discussions around incentives for localized vaccine production and workforce development. Collectively, these responses are shaping a more resilient but regionally differentiated production and distribution landscape for animal vaccines.

A comprehensive segmentation framework that aligns product modalities, animal categories, disease targets, administration routes, and distribution channels to inform differentiated development and commercialization approaches

Segmentation reveals distinct development, adoption, and commercialization dynamics that require tailored strategies across product types, target animals, disease categories, administration routes, and distribution pathways. Based on Product, the field includes inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines, each presenting different R&D timelines, manufacturing complexities, and cold-chain dependencies; these differences inform prioritization decisions for pipeline investment and capacity planning. Based on Animal Type, the market spans companion animals and livestock animals, where the Companion Animals category further differentiates into cats and dogs, and the Livestock Animals category further differentiates into cattle, poultry, sheep, and swine; this segmentation underscores that clinical needs, dosing regimens, and distribution models vary substantially between household pets and production animals, driving distinct commercial channels and communication strategies.

Based on Disease Type, attention must be allocated across bacterial infections, fungal infections, parasitic infections, and viral infections. Within bacterial infections, clinical focus areas include clostridial diseases, E. coli, leptospirosis, and pasteurella, while parasitic infections break down into ectoparasites and endoparasites. Viral infections demand specialized responses to agents such as avian influenza virus, bovine viral diarrhea virus (BVDV), foot-and-mouth disease virus (FMDV), Newcastle disease virus, porcine reproductive and respiratory syndrome virus (PRRSV), and rabies virus. Each disease subset drives different antigen design approaches, regulatory pathways, and field efficacy considerations. Based on Route of Administration, vaccines are delivered as injectable vaccines and oral vaccines, with injectable vaccines further categorized by intramuscular, intravenous, and subcutaneous routes; administration route affects compliance, training requirements for administers, and formulation constraints. Based on Distribution Channel, suppliers reach end-users through online pharmacies, retail pharmacies, and veterinary clinics, and each channel imposes unique handling, labeling, and service expectations. Integrating these segmentation lenses enables more precise product positioning, targeted clinical trial designs, and differentiated go-to-market strategies that align with the operational realities of veterinarians and producers.

Distinct regional priorities and infrastructure realities driving differentiated policy, manufacturing, and distribution strategies across the Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics frame distinct strategic priorities for vaccine developers, distributors, and policymakers, reflecting differences in regulatory regimes, production capacity, disease prevalence, and distribution infrastructure. In the Americas, there is a strong focus on regulatory harmonization, cold-chain modernization, and public-private partnerships to address both companion animal and livestock immunization needs. Regulatory agencies in this region emphasize demonstrable safety and efficacy, while industry actors pursue productivity gains through manufacturing automation and precision vaccination programs tied to surveillance data. Cross-border trade within the region supports consolidated production hubs, but recent policy shifts have incentivized greater supply diversification to reduce exposure to external shocks.

Europe, Middle East & Africa presents a mosaic of market conditions where advanced regulatory frameworks in some economies coexist with resource-constrained settings that require low-cost, thermostable formulations and decentralized distribution models. Demand in this region is influenced by strong animal welfare advocacy, stringent pathogen control standards, and a high level of veterinary professionalization in certain markets. Public health priorities drive collaborative initiatives for zoonotic disease prevention, while capacity gaps in parts of Africa and the Middle East create opportunities for novel delivery strategies and local manufacturing ventures.

Asia-Pacific continues to be a strategic focus due to its high livestock densities, diverse production systems, and rapidly modernizing veterinary sectors. Rapid urbanization, intensification of poultry and swine production, and persistent endemic and emerging viral threats place a premium on scalable vaccine solutions and rapid-response platforms. Governments in the region have shown interest in strengthening domestic biotech capabilities and in policies that support vaccine self-sufficiency, which creates an environment conducive to technology transfer, regional contract manufacturing, and collaborative surveillance networks. Across all regions, localized regulatory intelligence, disease profiling, and channel strategies are essential to unlocking adoption and sustaining immunization programs.

Market leaders and agile innovators are forging partnerships, securing specialized manufacturing capacity, and integrating services to convert technological advantage into durable commercial positioning

Competitive dynamics in the animal vaccines space are shaped by a mix of multinational firms, specialized biotech innovators, and contract manufacturers that provide flexible capacity. Established players continue to invest in portfolio diversification and manufacturing resilience, balancing legacy platforms such as inactivated and live attenuated vaccines with emerging technologies like mRNA and recombinant constructs. Specialized biotech entrants are advancing niche indications and platform capabilities, often partnering with contract development and manufacturing organizations to scale production rapidly and to de-risk capital-intensive facility builds. Meanwhile, contract manufacturers and service providers play an increasingly strategic role by offering modular, purpose-built capacity that shortens commercialization timelines and supports regional localization efforts.

Strategic collaborations, licensing agreements, and co-development models have become common, allowing organizations to combine scientific expertise, regulatory know-how, and distribution reach. Intellectual property around novel adjuvants, thermostable formulations, and antigen-display platforms is a critical differentiator, as is the ability to translate genomic surveillance insights into updated vaccine strains. Companies that integrate post-sale services-such as cold-chain monitoring, vaccination adherence platforms, and data analytics-enhance customer value and create stickiness with veterinarians and producers. In sum, the competitive landscape rewards agility in product innovation, manufacturing partnerships, and the ability to deliver end-to-end solutions that reduce operational friction for end-users.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate innovation, diversify production, and strengthen regulatory and commercial partnerships for vaccine resilience

Industry leaders should adopt a multi-pronged strategy that accelerates technological translation while strengthening supply chain redundancy and stakeholder engagement. First, prioritize platform-agnostic R&D investments that can be re-targeted across multiple disease indications to maximize the return on scientific advances and to shorten the time to field deployment. Second, develop flexible manufacturing networks by qualifying multiple contract manufacturers across regions and by investing selectively in modular, single-use technologies that enable rapid scale-up and reduce changeover times. Third, design formulations and packaging with real-world distribution constraints in mind, emphasizing thermostability and simplified administration routes to broaden access in decentralized delivery settings.

Additionally, cultivate closer collaboration with regulatory authorities to pilot adaptive approval pathways for novel modalities and to align on post-approval evidence generation. Strengthen relationships with veterinarians through education, data-driven outcomes measurement, and integrated service offerings that support vaccination adherence and herd-level decision-making. Finally, embed trade-risk mitigation into commercial planning by diversifying supplier bases, negotiating flexible contracting terms, and engaging with policymakers to support incentives for domestic capacity where strategic. Executing on these recommendations will increase resilience, accelerate adoption, and create measurable value for animal health stakeholders across companion and production animal segments.

A validated, multi-source research approach combining stakeholder interviews, technical literature review, and supply chain and policy analysis to produce actionable insights grounded in operational realities

This research synthesis draws on a triangulated methodology combining primary stakeholder engagement, technical literature review, and supply chain and policy analysis to ensure robust, actionable findings. Primary inputs included structured interviews with veterinary clinicians, vaccine developers, contract manufacturers, and distribution channel leaders to capture operational realities, unmet needs, and strategic intent. Technical literature and regulatory guidance documents were reviewed to validate scientific trends, modality-specific considerations, and recent policy developments affecting vaccine development and authorization.

Complementary analysis assessed trade and supply chain implications by examining tariff schedules, public procurement practices, and logistical constraints that influence distribution decisions. Comparative regional assessments were informed by disease surveillance reporting and veterinary infrastructure profiling to contextualize adoption barriers and opportunities. Findings were synthesized through an iterative validation process with subject-matter experts to ensure that recommendations reflect practical feasibility and regulatory realism. Throughout, care was taken to avoid extrapolating into speculative market sizing, instead focusing on structural drivers, operational implications, and decision-useful insights for leaders in the animal vaccines ecosystem.

A concise synthesis of how innovation, policy shifts, and operational resilience must be aligned to realize the full potential of vaccines in protecting animal health and public safety

The convergence of scientific innovation, changing trade policies, and region-specific disease pressures presents both challenges and opportunities for the animal vaccines ecosystem. Advances in platform technologies and formulation science create pathways to more effective and accessible vaccines, yet these gains must be matched by investments in manufacturing flexibility, distribution resilience, and regulatory collaboration. Tariff shifts and geopolitical considerations have underscored the strategic importance of supply diversification and regional capacity, while evolving end-user expectations demand products that are not only efficacious but also practical to deploy in real-world veterinary settings.

Going forward, success will favor organizations that integrate technological agility with operational robustness and stakeholder-centric commercialization strategies. Collaboration across the value chain-from tech developers and contract manufacturers to veterinarians and distributors-will accelerate translational success and enhance impact. By aligning R&D priorities with pragmatic delivery solutions and policy engagement, industry actors can strengthen animal health outcomes, protect food systems, and reduce zoonotic risk in an increasingly interconnected world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of mRNA and DNA vaccine platforms to tackle emerging zoonotic threats
  • 5.2. Growing integration of autogenous vaccines to address farm-specific pathogen outbreaks in swine herds
  • 5.3. Increased use of DIVA vaccine strategies for differentiating infected from vaccinated animals in avian flu control
  • 5.4. Advances in nanoparticle adjuvants enhancing immunogenicity of equine influenza vaccines across global markets
  • 5.5. Emergence of combination vaccines targeting multiple clostridial and bacterial pathogens in ruminant livestock health
  • 5.6. Expansion of regulatory frameworks supporting conditional approval of emergency animal vaccines during disease outbreaks
  • 5.7. Implementation of precision livestock vaccination programs powered by farm data analytics and IoT monitoring devices
  • 5.8. Surge in demand for single-dose sustained-release formulations optimizing labor and compliance in poultry immunization
  • 5.9. Strategic partnerships between biotech firms and veterinary service providers for vaccine distribution in remote regions
  • 5.10. Development of thermostable vaccine formulations reducing cold chain dependency in tropical livestock markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Vaccines Market, by Product

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. mRNA Vaccines
  • 8.4. Recombinant Vaccines
  • 8.5. Subunit Vaccines

9. Animal Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Animal Vaccines Market, by Disease Type

  • 10.1. Bacterial Infections
    • 10.1.1. Clostridial
    • 10.1.2. E. Coli
    • 10.1.3. Leptospirosis
    • 10.1.4. Pasteurella
  • 10.2. Fungal Infections
  • 10.3. Parasitic Infections
    • 10.3.1. Ectoparasites
    • 10.3.2. Endoparasites
  • 10.4. Viral Infections
    • 10.4.1. Avian Influenza Virus
    • 10.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 10.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 10.4.4. Newcastle Disease Virus
    • 10.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 10.4.6. Rabies Virus

11. Animal Vaccines Market, by Route of Administration

  • 11.1. Injectable Vaccines
    • 11.1.1. Intramuscular (IM)
    • 11.1.2. Intravenous (IV)
    • 11.1.3. Subcutaneous (SC)
  • 11.2. Oral Vaccines

12. Animal Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Animal Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Biogenesis Bago S.A.
    • 16.3.2. BioVaxys Technology Corporation
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Brilliant Bio Pharma Private limited
    • 16.3.5. Ceva Sante Animale
    • 16.3.6. China Animal Husbandry Industry Co., Ltd.
    • 16.3.7. Dalan Animal Health
    • 16.3.8. Elanco Animal Health Inc.
    • 16.3.9. Endovac Animal Health, LLC by Immvac Inc.
    • 16.3.10. Hester Biosciences Limited
    • 16.3.11. HIPRA, S.A.
    • 16.3.12. Indian Immunologicals Limited
    • 16.3.13. Kemin Industries, Inc.
    • 16.3.14. Merck KGaA
    • 16.3.15. Neogen Corporation
    • 16.3.16. Phibro Animal Health Corporation
    • 16.3.17. SAN Vet Holding GmbH
    • 16.3.18. Sanofi S.A.
    • 16.3.19. Seppic S.A.
    • 16.3.20. Torigen Pharmaceuticals Inc.
    • 16.3.21. Vaxxinova GmbH
    • 16.3.22. VEROVACCiNES GmbH
    • 16.3.23. Vetigenics, LLC
    • 16.3.24. Vetoquinol SA
    • 16.3.25. Virbac, Inc.
    • 16.3.26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025-2032 (U